Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial

By sjmartinez • August 31, 2023

Moser CB, Chew KW, Ritz J, Newell M, Javan AC, Eron JJ, Daar ES, Wohl DA, Currier JS, Smith DM, Hughes MD; ACTIV-2/A5401 Study Team. Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial. J Infect Dis. 2023 Aug 31;228(Supplement_2):S92-S100. doi: 10.1093/infdis/jiad209. PMID: 37650234.

Tags: adaptive platform trials, covid-19, Harbor UCLA, Infectious Diseases, pooled placebo, Publications, randomization

Large-scale multi-omics analyses in Hispanic/Latino populations identify genes for cardiometabolic traits

Petty LE, Chen HH, Frankel EG, Zhu W, Downie CG, Graff M, Lin P, Sharma P, Zhang X, Scartozzi AC, Roshani R, Landman JM, Boehnke[...]

Racial and Ethnic Differences in Long-Term Cardiovascular Mortality Among Women and Men From the CAC Consortium

Rosenblatt S, Blaha MJ, Blankstein R, Nasir K, Lin F, Yeboah-Kordieh Y, Berman DS, Miedema MD, Whelton SP, Rumberger J, Budoff MJ, Leipsic J, Shaw[...]

Optimizing optical coherence tomography to detect occult spermatozoa in rat testis after induced non-obstructive azoospermia

Yu L, Lue Y, Yang H, Liu J, Vega C, Ho K, Rajfer J, Wang C, Swerdloff R, Hyle Park B. Optimizing optical coherence tomography[...]